Orchestra BioMed Holdings Inc. (OBIO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $570.61M
Last updated: Nov 17, 2026 at 11:05 AM ET
Orchestra BioMed Holdings Inc. (OBIO) Stock Forecast
Analysts expect Orchestra BioMed Holdings (OBIO) to earn -$1.52 per share in the fiscal year ending Dec 31, 2026, on revenue of $451140. Of 7 analysts, 7 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 1.86, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 14.3% |
| Buy | 6 | 85.7% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 40.4%.
- Fiscal year ending Dec 31, 2026
- -$1.52
- EPS consensus, revenue $451140
- Fiscal year ending Dec 31, 2027
- -$1.50
- EPS consensus, revenue $633500
- Next report
- Mar 10, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.52 | -$1.65 to -$1.46 | 6 | $451140 | $378000 to $700000 | 7 |
| Dec 31, 2027 | -$1.50 | -$1.80 to -$1.30 | 6 | $633500 | $360000 to $1.28M | 6 |
Quarterly Estimates
The EPS consensus rises from -$0.39 for the quarter ending Dec 31, 2026 to -$0.37 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.39 | -$0.40 to -$0.35 | 9 | $112200 | $88200 to $168000 | 9 |
| Mar 31, 2027 | -$0.37 | -$0.42 to -$0.32 | 3 | $102200 | $90000 to $121000 | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 8 upward and 3 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 1 |
| Fiscal year ending Dec 31, 2027 | 4 | 1 |
| Quarter ending Mar 31, 2027 | 2 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.50.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.52 | -$1.52 | -$1.52 | -$1.52 | -$1.50 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.50 | -$1.51 | -$1.51 | -$1.52 | -$1.52 | N/A |
| Quarter ending Mar 31, 2027 | -$0.37 | -$0.37 | -$0.37 | -$0.37 | -$0.36 | N/A |
Frequently Asked Questions About OBIO
What is the OBIO stock forecast?
Consensus analyst estimates put Orchestra BioMed Holdings's EPS at -$1.52 for the fiscal year ending Dec 31, 2026, on revenue of $451140. The consensus rating from 7 analysts is Buy.
How do analysts rate OBIO stock?
Of 7 analysts covering Orchestra BioMed Holdings, 1 rates it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from OBIO next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.52, with estimates from -$1.65 to -$1.46 from 6 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.50, with estimates from -$1.80 to -$1.30 from 6 analysts.
What revenue do analysts expect from Orchestra BioMed Holdings next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $451140, with estimates from $378000 to $700000. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $633500, with estimates from $360000 to $1.28M.
How many analysts cover OBIO?
7 analysts rate Orchestra BioMed Holdings stock, and 6 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
OBIO pages: Overview, Earnings, Forecast, Financials, Competitors